Nalin Mehta, MD
Ophthalmology · Lakewood, CONPI 1720180334
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,136 of the $80,862 with a category attached, or 78.1%. Regeneron Healthcare Solutions, Inc. accounts for 95.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $54,021 and has fallen 99.1% since, to $492 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $475.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$77K
- Eyepoint US, Inc.$565
- BD$492
- Alimera Sciences, Inc.$442
- Regeneron$441
- AbbVie$343
- plus $1K from 19 others
What the payments were for
- Consulting fees$4921%
- Speaking & faculty fees$63,13678%
- Travel & lodging$11,60514%
- Food & beverage$5,5597%
- Gifts$190%
- Entertainment$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 105 | $77,093 |
| Eyepoint US, Inc. | 7 | $565 |
| BD | 1 | $492 |
| Alimera Sciences, Inc. | 6 | $442 |
| Regeneron | 8 | $441 |
| AbbVie(2 entities) | 9 | $343 |
| Apellis Pharmaceuticals, Inc. | 5 | $292 |
| Astellas Pharma US Inc | 4 | $185 |
| Genentech USA, Inc. | 3 | $165 |
| Genentech, Inc. | 1 | $131 |
| Carl Zeiss Meditec USA, Inc. | 1 | $128 |
| Maculogix, Inc. | 2 | $121 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $88 |
| Mallinckrodt Hospital Products Inc. | 3 | $75 |
| Optos, Inc. | 1 | $50 |
| Notal Vision, Inc. | 2 | $37 |
| Novartis | 2 | $34 |
| Bausch & Lomb Americas Inc. | 1 | $33 |
| Carl Zeiss Meditec, Inc. | 1 | $25 |
| Biogen | 1 | $24 |
| Vyera Pharmaceuticals, LLC | 1 | $22 |
| Spark Therapeutics, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,862 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 50 | $111,362 |
| MoxifloxacinMoxifloxacin Hcl | 32 | $748 |
| Ofloxacin | 22 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $77,093 | $111,36250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Lakewood
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.